<b>Objective</b>: To examine patterns of inflammatory markers, kidney function, and clinical outcomes in patients with type 2 diabetes (T2D) hospitalized for COVID-19, with particular focus on the impact of therapy with hydroxymethylglutaryl-CoA reductase inhibitors (statins). Here, HMGCR is linked to COVID-19.